Sloss, Callum M <br/><br/>
Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Aug 2008 
 - 5116-23 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1078-0432 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-07-4506  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Animals<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Apoptosis--drug effects<br/>Bevacizumab<br/>Blotting, Western<br/>Boronic Acids--administration & dosage<br/>Bortezomib<br/>Cell Line, Tumor<br/>Cetuximab<br/>Deoxycytidine--administration & dosage<br/>ErbB Receptors--drug effects<br/>Erlotinib Hydrochloride<br/>Female<br/>Humans<br/>Lactones--administration & dosage<br/>Mice<br/>Mice, Nude<br/>Pancreatic Neoplasms--drug therapy<br/>Phosphatidylinositol 3-Kinases--drug effects<br/>Protease Inhibitors--therapeutic use<br/>Proteasome Inhibitors<br/>Pyrazines--administration & dosage<br/>Pyrroles--administration & dosage<br/>Quinazolines--administration & dosage<br/>Signal Transduction--drug effects<br/>Xenograft Model Antitumor Assays<br/>Gemcitabine